Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
14 studies found for:    gdc0032
Show Display Options
Rank Status Study
1 Recruiting Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen
Conditions: Breast Cancer;   Ovarian Cancer;   Cancer of the Uterus
Interventions: Drug: GDC-0032;   Drug: Tamoxifen
2 Recruiting A Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
Condition: Breast Cancer
Interventions: Drug: GDC-0032;   Drug: Letrozole;   Other: Placebo
3 Recruiting A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Condition: Non-Hodgkin's Lymphoma, Solid Cancers
Interventions: Drug: Fulvestrant;   Drug: GDC-0032;   Drug: Letrozole
4 Completed A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers
Condition: Healthy Volunteer
Interventions: Drug: GDC-0032;   Drug: Itraconazole;   Drug: Rifampin
5 Completed A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers
Condition: Healthy Volunteer
Intervention: Drug: GDC-0032
6 Active, not recruiting A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Condition: Breast Cancer, Non-small Lung Cancer
Interventions: Drug: Docetaxel;   Drug: GDC-0032;   Drug: Paclitaxel
7 Recruiting Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Taselisib
8 Completed A Study of the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers
Condition: Healthy Volunteer
Intervention: Drug: GDC-0032
9 Recruiting Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Conditions: Metastatic Breast Cancer;   Recurrent Breast Cancer
Interventions: Drug: Taselisib;   Drug: Trastuzumab emtansine;   Drug: Pertuzumab;   Drug: Trastuzumab;   Drug: Paclitaxel
10 Recruiting Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Biomarker Analysis;   Drug: Enzalutamide;   Other: Pharmacological Study;   Drug: Taselisib
11 Recruiting PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib
Conditions: Advanced Solid Tumours;   Breast Cancer
Intervention: Drug: Palbociclib + Taselisib / Pictilisib
12 Recruiting SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
Condition: Breast Cancer
Interventions: Drug: fulvestrant;   Drug: placebo;   Drug: taselisib
13 Recruiting Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Drug: Docetaxel;   Biological: Durvalumab;   Drug: Erlotinib Hydrochloride;   Drug: FGFR Inhibitor AZD4547;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Palbociclib;   Biological: Rilotumumab;   Drug: Taselisib
14 Recruiting NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Conditions: Advanced Malignant Neoplasm;   Lymphoma;   Refractory Malignant Neoplasm;   Solid Neoplasm
Interventions: Drug: Afatinib;   Drug: Akt inhibitor AZD5363;   Drug: Binimetinib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Vismodegib

Study has passed its completion date and status has not been verified in more than two years.